In the last year, shares of Gilead Sciences (GILD) are down 32%. With competition increasing for its hepatitis-C treatment, it is unlikely shareholders will see any relief.
Patients and doctors were outraged in 2013 when Gilead Sciences priced its breakthrough cure Sovaldi, for the treatment of hepatitis C, at $84,000 (or $1,000 per pill) for a 12-week regimen.
Within a year, the FDA approved the company's latest hep-C drug, Harvoni, at $94,000 ($1,125 per pill) for a 12-week treatment.
Patients and doctors were outraged in 2013 when Gilead Sciences priced its breakthrough cure Sovaldi, for the treatment of hepatitis C, at $84,000 (or $1,000 per pill) for a 12-week regimen.
Within a year, the FDA approved the company's latest hep-C drug, Harvoni, at $94,000 ($1,125 per pill) for a 12-week treatment.
